Ofri Mosenzon

21PUBLICATIONS
49CO-AUTHORS
Molecular targetsBehavioural epidemiologyEpidemiological modellingGene expression (incl. microarray and other genome-wide approaches)Cardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Aug 09, 2023
Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes.

Filipe A Moura, David D Berg, Andrea Bellavia

|Jul 04, 2023
The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study.

Peter Rossing, Stefan D Anker, Gerasimos Filippatos

|Jun 29, 2023
Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data.

Meir Schechter, Cheli Melzer Cohen, Tamir Zelter

|Jun 29, 2023
Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney Disease.

Cheli Melzer Cohen, Meir Schechter, Aliza Rozenberg

|Dec 05, 2022
Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease : A Post Hoc Analysis of DAPA-CKD.

Meir Schechter, Niels Jongs, Glenn M Chertow

|Oct 06, 2022
Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study.

Helena Bleken Østergaard, Valerie Humphreys, Ellen Margo Hengeveld

Pageof 4

Frequent Collaborators

5 joint publications

Itamar Raz

4 joint publications

Ofri Mosenzon

4 joint publications

Meir Schechter

3 joint publications

Lawrence A Leiter